ProCE Banner Series

Applying Evidence-Based Strategies to Improve Outcomes in HER2-Negative Early Breast Cancer

Join us for this interactive, 1-hour, CPE-certified webinar featuring expert perspectives on best practices in the implementation of targeted therapy and immunotherapy-based (neo)adjuvant treatment regimens for HER2-negative early breast cancer.

  ACPE-P
Who Should Attend

This program is intended for oncology/hematology pharmacists and other clinical practice stakeholders involved in the care of patients with EBC.

All Events

Applying Evidence-Based Strategies to Improve Outcomes in HER2-Negative Early Breast Cancer

Upcoming Events

May

02

2024

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
Assistant Adjunct Professor
UK College of Pharmacy
Lexington, Kentucky

ProCE Banner Faculty
Jordan Hill, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
West Virginia University Cancer Institute
Morgantown, West Virginia

Topics

Breast Cancer

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of healthcare professional learners in the management of patients with EBC. 

Target Audience
This program is intended for oncology/hematology pharmacists and other clinical practice stakeholders involved in the care of patients with EBC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate current and emerging published data and consensus-based guidelines to determine the appropriate use of biomarkers and genomic classifiers for assessing the risk of recurrence in patients with EBC 
  • Develop personalized neoadjuvant/adjuvant treatment strategies with approved targeted or immunotherapy agents for patients with HR+/HER2- EBC  
  • Select appropriate strategies to anticipate, monitor, and manage adverse events with current and emerging therapies for HR+/HER2- EBC to improve adherence and optimize outcomes 
  • Identify patients who meet the eligibility criteria for ongoing clinical trials investigating novel therapies for HR+/HER2- EBC

Accreditation

CE Accreditation

Pharmacists

This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-24-007-L01-P has been assigned to this live application-based activity (initial release date 05/02/2024). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.